Agilent Technologies stock climbs after Q3 2026 beat and guidance raise
Published on 08/27/2026 at 08:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Agilent Technologies Inc. (ISIN US00846U1016) delivered a stronger-than-expected third quarter for fiscal 2026, with the stock moving higher after the company beat Wall Street estimates and raised its full-year outlook as reported on August 26, 2026. Per recent earnings summaries, the life sciences and diagnostics group posted solid revenue growth, expanding margins and a higher guidance range for both revenue and earnings for the current fiscal year. For investors, the combination of accelerating core growth and disciplined profitability is now central to the Agilent Technologies stock story.
Q3 2026 earnings beat expectations
According to a detailed Q3 2026 earnings overview, Agilent reported third quarter fiscal 2026 revenue of $1.88 billion for the period ended July 31, 2026, representing reported growth of 8.1 percent year over year. An earnings summary notes that core revenue growth, which strips out currency and acquisition effects, reached 7.3 percent compared with the third quarter of fiscal 2025, underscoring improving demand across key end markets.
On the bottom line, the same overview states that Agilent generated GAAP net income of $362 million in Q3 fiscal 2026, equal to $1.28 per share, up from the prior-year quarter. An earnings call transcript highlights that non-GAAP diluted earnings per share reached $1.62, compared with a consensus estimate of $1.49, implying that Agilent exceeded forecasts by $0.13 per share and delivered double-digit percentage EPS growth versus the previous year on an ex-tariff-refund basis.
Market data from an earnings report page confirms that the third-quarter EPS of $1.62 compared with $1.37 per share one year earlier, an increase of 18.2 percent year over year. The same earnings dashboard lists Q3 2026 revenue at $1.88 billion versus $1.84 billion expected, meaning Agilent beat consensus revenue estimates by $36.51 million and delivered 8.1 percent reported growth compared with the prior-year quarter.
Guidance raised for fiscal 2026 and Q4
Beyond the quarterly beat, updated outlook figures provide insight into management's confidence for the rest of fiscal 2026. A guidance summary notes that for the full fiscal year 2026, Agilent now expects net revenue between $7.49 billion and $7.51 billion, which represents an increase of $60 million at the midpoint compared with its prior forecast. The same source indicates that core revenue growth is projected at 5.8 to 6.0 percent for the year, with the midpoint 65 basis points higher than the previous core growth outlook, signaling an improved demand backdrop.
In terms of profitability, earnings call highlights show that Agilent now forecasts full-year 2026 adjusted EPS in a range of $6.18 to $6.21, including the effect of tariff refunds, with a midpoint around $6.195 that stands above earlier consensus estimates. The earnings call highlights further indicate that on an ex-refund basis, the company expects adjusted EPS between $6.12 and $6.15, reinforcing the message that underlying profitability is improving even when one-off tariff benefits are excluded.
Looking to the nearer term, a Q3 results summary citing management guidance states that for the fourth quarter of fiscal 2026, Agilent anticipates revenue of $1.98 billion to $2.00 billion, which implies reported growth of 6.4 to 7.4 percent and core revenue growth in a range of 5.2 to 6.2 percent. An overview of the related regulatory filing attributes this outlook to sustained strength in key segments and ongoing operational efficiencies, which together support higher margins as volumes increase.
Stock reaction and valuation context
Agilent shares reacted positively to the earnings and guidance news. A same-day market report notes that the company's shares rose 3.17 percent in after-hours trading on August 26, 2026, to $160.00, after closing the regular session at $155.08. The report adds that the after-hours level left the stock close to its 52-week high of $160.51, underlining how the earnings beat and guidance hike reinforced an already strong price performance.
Another performance review points out that over the 30 days leading up to August 21, 2026, Agilent shares climbed from a closing price of $138.57 on July 24, 2026, to approximately $159.00, representing a gain of 14.7 percent. This 30-day momentum analysis highlights that the stock's rally into the earnings event reflected growing investor confidence, and the subsequent move toward the 52-week high as of late August 2026 indicates that the strong Q3 delivery helped justify that optimism.
A valuation-focused commentary on the Q3 report notes that a fair value framework assigned a reference value of $147.01 to the stock, compared with a regular-session price of $155.08 on August 26, 2026. The same valuation discussion concludes that at that time the shares traded roughly 5.5 percent above the model's estimated intrinsic value, suggesting that the market was willing to pay a modest premium for Agilent's growth and margin profile after the earnings beat and outlook upgrade.
Analyst expectations and market positioning
Before the earnings release, a pre-result preview highlighted that analysts on average expected Agilent to report Q3 fiscal 2026 earnings of $1.49 per share on revenue of $1.84 billion, essentially calling for flat profitability compared with the prior quarter and only slightly higher sales. The preview piece also summarized that the stock carried a consensus recommendation equivalent to a moderate buy rating, with a mean price target of $160.85, implying single-digit percentage upside from a pre-earnings price of $154.77.
The same analyst roundup described specific target changes, noting that one firm raised its Agilent price target to $175 from $160 on August 13, 2026, while another lifted its target to $150 from $135 on August 21, 2026, and that 16 of 22 covering analysts rated the stock as a buy with six holds and no sell ratings. These moves indicate that positive revisions to earnings expectations and greater confidence in margin resilience were already feeding into valuation models even ahead of the Q3 print, helping to underpin the stock's advance toward its 52-week high.
Post-earnings, an earnings-surprise review confirms that Agilent's adjusted EPS of $1.62 in Q3 fiscal 2026 exceeded a consensus forecast of $1.48 per share, yielding an earnings surprise of 9.46 percent. The same overview reports that for the coming quarter, the current consensus EPS estimate stands at $1.71 on revenue of $1.97 billion, while the consensus for the full fiscal year anticipates EPS of $6.05 on revenue of $7.45 billion, figures that now sit below the company's updated guidance ranges for fiscal 2026, suggesting room for further upward estimate revisions if execution remains strong.
Profitability, cash flow and balance sheet trends
Beyond headline revenue and EPS, the latest quarter showed notable improvements in profitability and cash generation. According to the earnings call transcript, Agilent delivered a gross margin of 56.4 percent in Q3 fiscal 2026, or 54.9 percent when excluding benefits from tariff refunds, indicating that underlying gross profitability remains robust even without one-off factors. The call commentary further points out that ex-refund earnings per share of $1.56 were $0.06 above the high end of guidance and represented 14 percent year-over-year growth, underscoring the strength of Agilent's operational leverage.
Another detailed Q3 performance summary echoes these trends, indicating that operating profit increased to $444 million in the quarter, up 23.3 percent from the prior-year period, while diluted EPS of $1.28 on a GAAP basis rose 8.5 percent year over year. The same report highlights that cash from operating activities climbed to $519 million in Q3 fiscal 2026, up 43.4 percent compared with a year earlier, and that capital expenditures were kept at $80 million, supporting a stronger free cash flow profile.
The cash and balance sheet position also appears solid. The Q3 summary notes that Agilent ended the quarter with $1.8 billion in cash and cash equivalents and total liabilities of $6.6 billion. This combination gives the company flexibility to continue investing in growth initiatives, while maintaining the capacity to navigate cycles in end-market demand. For equity investors, the ability to generate higher cash flows while expanding margins and keeping leverage in check reinforces the argument that the business can fund its own growth and shareholder returns.
End-market dynamics and segment performance
Management's commentary around the Q3 2026 results emphasizes that demand conditions have improved across several of Agilent's core end markets. The earnings call transcript notes that core revenue growth of 7.3 percent in the quarter exceeded the high end of guidance by 140 basis points, reflecting stronger than anticipated uptake in analytical instrumentation and related services. The same discussion mentions that one of the company’s key divisions, described as LDG, delivered 10 percent core revenue growth in Q3 fiscal 2026, outpacing aggregate company growth and pointing to robust activity in that segment.
These segment trends have strategic implications. Faster growth in areas such as lab diagnostics and genomics, chromatography and mass spectrometry solutions can help Agilent shift its mix toward higher-value, higher-margin businesses over time. Combined with operating discipline, this mix effect can support sustained margin expansion even when overall revenue growth remains in the mid-single-digit range on a core basis. For Agilent Technologies stock, sustained evidence that these higher-growth segments are pulling ahead of the broader portfolio is a key underpinning for the current valuation premium.
In addition, management has highlighted the benefits of its Ignite program, an internal effort aimed at structural improvements in operations and efficiency. The transcript indicates that cost initiatives and productivity improvements contributed to the ability to deliver 14 percent year-over-year growth in ex-refund EPS on revenue growth of 7.3 percent on a core basis, demonstrating positive operating leverage. If such programs continue to yield benefits, they can help Agilent maintain or extend its margin profile even as it steps up investment in R&D and commercial capabilities.
Representative product: Agilent 1260 Infinity II LC system
A concrete example of Agilent's product portfolio is its 1260 Infinity II liquid chromatography system, a widely used platform in analytical laboratories for separating and quantifying compounds in complex samples. The system is designed to deliver high throughput and robust performance for applications spanning pharmaceuticals, food safety, environmental testing and chemical analysis, and can be configured with various detectors and modules to match specific customer workflows. As labs seek to improve productivity while maintaining precision, platforms in this class enable users to handle larger sample volumes, automate methods and integrate data analysis, supporting the type of recurring demand that underpins Agilent's installed base and consumables business.
Agilent Technologies stock and recent price levels
Agilent Technologies shares trade on the New York Stock Exchange under the ticker symbol A, with trading in U.S. dollars. A post-earnings market report records that the stock closed the regular session on August 26, 2026, at $155.08, then moved up 3.17 percent in after-hours trading to $160.00, placing the price close to the stated 52-week high of $160.51. For investors, this positioning just below the one-year high after an 8.1 percent year-over-year revenue increase and an 18.2 percent jump in adjusted EPS compared with the prior-year quarter illustrates how the latest results and guidance have reinforced confidence in the company's medium-term growth and profitability trajectory.
Read more
More on Agilent Technologies stock and company information
Fact box
Company: Agilent Technologies Inc.
ISIN: US00846U1016
Ticker: A
Exchange: New York Stock Exchange (NYSE)
Sector / Industry: Life sciences tools and diagnostics
